CSIMarket
 


Eyenovia inc   (EYEN)
Other Ticker:  
 

Eyenovia Inc 's Quick Ratio

EYEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Quick Ratio fell to 1.56 below Eyenovia Inc average.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Quick Ratio than Eyenovia Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 759, from total ranking in the third quarter 2023 at 922.

Explain Quick Ratio?
How much Cash & cash equivalents EYEN´s has?
What are EYEN´s Current Liabilities?


EYEN Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 111.21 % -32.01 % -63.57 % -50.86 % -56.3 %
Y / Y Cash & cash equivalent Change -35.38 % 18.99 % -18.78 % -30.43 % 18.09 %
Quick Ratio MRQ 1.56 3.16 4.3 3.79 5.09
EYEN's Total Ranking # 759 # 922 # 800 # 947 # 827
Seq. Current Liabilities Change 45.54 % 61.12 % -17.08 % 8.62 % -53.15 %
Seq. Cash & cash equivalent Change -28.27 % 18.51 % -6.01 % -19.13 % 32.1 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 268
Overall Market # 757


Quick Ratio Statistics
High Average Low
50.26 8.42 1.04
(Mar 31 2018)   (Sep 30 2021)




Financial Statements
Eyenovia Inc 's Current Liabilities $ 10 Millions Visit EYEN's Balance sheet
Eyenovia Inc 's Cash & cash equivalent $ 15 Millions Visit EYEN's Balance sheet
Source of EYEN's Sales Visit EYEN's Sales by Geography


Cumulative Eyenovia Inc 's Quick Ratio

EYEN's Quick Ratio for the trailling 12 Months

EYEN Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 111.21 % -32.01 % -63.57 % -50.86 % -56.3 %
Y / Y Cash & cash equivalent TTM Growth -35.38 % 18.99 % -18.78 % -30.43 % 18.09 %
Quick Ratio TTM 2.86 3.98 3.31 2.66 2.51
Total Ranking TTM # 519 # 700 # 3677 # 3548 # 635
Seq. Current Liabilities TTM Growth 45.54 % 61.12 % -17.08 % 8.62 % -53.15 %
Seq. Cash & cash equivalent TTM Growth -28.27 % 18.51 % -6.01 % -19.13 % 32.1 %


On the trailing twelve months basis Due to jump in Current Liabilities in the IV Quarter 2023 to $9.53 millions, cumulative Quick Ratio decreased to 2.86 below the Eyenovia Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Quick Ratio than Eyenovia Inc . While Quick Ratio overall ranking has improved so far to 519, from total ranking during the twelve months ending third quarter 2023 at 700.

Explain Quick Ratio?
How much Cash & cash equivalents EYEN´s has?
What are EYEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 116
Healthcare Sector # 228
Within the Market # 519


trailing twelve months Quick Ratio Statistics
High Average Low
16.77 4.39 1.46
(Sep 30 2018)   (Sep 30 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Adc Therapeutics Sa  4.21 $ 278.598  Millions$ 66.203  Millions
Arcus Biosciences Inc   4.13 $ 759.000  Millions$ 184.000  Millions
Aadi Bioscience Inc   4.12 $ 108.845  Millions$ 26.395  Millions
Intra cellular Therapies Inc   4.03 $ 497.941  Millions$ 123.545  Millions
Foghorn Therapeutics Inc   4.01 $ 234.057  Millions$ 58.436  Millions
Zai Lab Limited  3.97 $ 806.451  Millions$ 203.067  Millions
Corvus Pharmaceuticals Inc   3.95 $ 27.149  Millions$ 6.869  Millions
Arcutis Biotherapeutics Inc   3.93 $ 183.463  Millions$ 46.668  Millions
Aclaris Therapeutics Inc   3.90 $ 119.106  Millions$ 30.526  Millions
United Therapeutics Corporation  3.89 $ 2,994.100  Millions$ 769.000  Millions
Regeneron Pharmaceuticals Inc   3.66 $ 10,844.800  Millions$ 2,964.500  Millions
Ardelyx Inc   3.66 $ 184.299  Millions$ 50.393  Millions
Citius Pharmaceuticals Inc   3.65 $ 20.384  Millions$ 5.579  Millions
Benitec Biopharma Inc   3.55 $ 20.399  Millions$ 5.746  Millions
Vanda Pharmaceuticals Inc   3.53 $ 135.821  Millions$ 38.460  Millions
Corcept Therapeutics Inc  3.52 $ 368.221  Millions$ 104.505  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Schrodinger Inc   3.46 $ 463.003  Millions$ 133.673  Millions
Moleculin Biotech Inc   3.46 $ 23.550  Millions$ 6.815  Millions
Context Therapeutics Inc   3.45 $ 14.450  Millions$ 4.192  Millions
Theriva Biologics inc   3.44 $ 23.177  Millions$ 6.738  Millions
Blueprint Medicines Corporation  3.31 $ 710.641  Millions$ 214.923  Millions
Kiniksa Pharmaceuticals ltd   3.24 $ 206.371  Millions$ 63.666  Millions
Travere Therapeutics Inc   3.19 $ 566.851  Millions$ 177.908  Millions
Deciphera Pharmaceuticals Inc   3.16 $ 306.216  Millions$ 96.771  Millions
Vertex Pharmaceuticals Inc  3.16 $ 11,218.300  Millions$ 3,547.400  Millions
Revance Therapeutics Inc   2.85 $ 254.465  Millions$ 89.224  Millions
Hookipa Pharma inc   2.79 $ 117.096  Millions$ 41.988  Millions
G1 Therapeutics Inc   2.76 $ 82.156  Millions$ 29.716  Millions
Mersana Therapeutics Inc   2.74 $ 174.561  Millions$ 63.637  Millions

Date modified: 2024-03-19T10:14:58+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com